Sunshine Biopharma, Inc.

87 articles with Sunshine Biopharma, Inc.

• Sunshine Biopharma Receives $0.9 Million in Additional Funding From RB Capital

  7/20/2021

  Sunshine Biopharma Inc. today announced that it has received additional funding from RB Capital Partners, Inc. (“RB Capital”) in the amount of $900,000.

• Sunshine Biopharma Employs mRNA Vaccine Technology to Expand Its Fight Against Multidrug Resistant Cancer

  7/8/2021

  Sunshine Biopharma Inc. today announced that it has succeeded in inhibiting the activity of Nrf2 using mRNA vaccine technology. Nrf2 is a transcription factor responsible for activation of oxidative stress genes as well as the cancer multidrug resistance genes, MDR1 (p-Glycoprotein), MRP1 and BCRP.

• Sunshine Biopharma Mice Study for COVID-19 Treatment Progressing as Planned

  6/9/2021

  Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, confirmed that its COVID-19 mice study currently underway at the University of Georgia is progressing as planned.

• Sunshine Biopharma’s Adva-27a Destroys Cancer Cells Expressing P-glycoprotein, a Marker Present in Over 50% of All Cancer Types

  5/25/2021

  Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, announced that it has elucidated the mechanism of action of Adva-27a, the Company’s flagship anticancer drug candidate.

• Sunshine Biopharma Eliminates $250,000 in Variable Rate Convertible Debt and Provides an Update on Status of OTCQB Uplisting

  5/20/2021

  Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has paid off $250,000 in variable rate convertible debt and is planning to soon eliminate the two similar items remaining on the books of the Company.

• Sunshine Biopharma Reports Improved Cash Position in 2021Q1 Filing

  5/13/2021

  Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs, announced that it has filed its 2021 first quarter report. The Report shows that the Company had Cash & Cash Equivalents of $1,796,596 as of March 31, 2021, the period end.

• Sunshine Biopharma Upgrades COVID-19 Provisional Patent Application to Full PCT Application

  5/4/2021

  Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, announced that it has timely filed a nonprovisional patent application in the form of a PCT in the United States for its COVID-19 treatment under development.

• RB Capital Increases Investment in Sunshine Biopharma

  4/22/2021

  Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that RB Capital has injected an additional investment of $500,000 to augment the Company’s Coronavirus drug development program.

• Sunshine Biopharma Reports Favorable MTD Results for COVID-19 Treatment

  4/19/2021

  Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has successfully completed a Maximum Tolerated Dose (MTD) study in mice.

• Sunshine Biopharma Reaches $2,000,000+ Financing for Coronavirus Treatment

  3/23/2021

  Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received a total of $2,054,000 to date from the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc.

• Sunshine Biopharma Receives Notice of Allowance for a New Patent Application Extending Protection of Adva-27a in Europe Until 2033

  3/11/2021

  Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has received a “Notice of Allowance” from the European Patent Office for a new patent application covering Adva-27a, the Company’s flagship anticancer compound.

• Sunshine Biopharma Receives Recently Ordered New Batch of Adva-27a and Initiates QA/QC Testing

  3/4/2021

  Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, announced that it has received shipment of a new batch of Adva-27a from its manufacturer in China.

• Sunshine Biopharma Initiates COVID-19 Treatment Mice Study

  2/10/2021

  Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has initiated a momentous transgenic mice study of its COVID-19 treatment that has been under development since May of last year.

• Sunshine Biopharma Signs Exclusive License Agreement With University of Georgia for COVID-19 Compounds

  2/4/2021

  Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has signed an exclusive license agreement with the University of Georgia for two Anti-Coronavirus compounds which UGA had previously developed and patented. Sunshine Biopharma and UGA will advance the development of these two compounds

• Sunshine Biopharma Receives Notice of Allowance for a New Patent Application Extending Protection of Adva-27a in Canada Until 2033

  2/2/2021

  Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has received a ;Notice of Allowance from the Canadian Intellectual Property Office for a new patent application covering Adva-27a, the Companys flagship anticancer compound.

• Sunshine Biopharma Completes Application to Uplist to OTCQB

  1/27/2021

  Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has successfully completed and submitted the application to uplist to the OTCQB.

• Sunshine Biopharma Receives Fourth Tranche From Previously Announced $2,000,000 + Financing for Coronavirus Treatment

  1/14/2021

  Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, announced that it has received the fourth tranche of funding under the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc.

• Sunshine Biopharma’s Coronavirus Treatment Anticipated to Be Effective Against the New Variant Identified in the UK

  12/22/2020

  Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that its Anti-Coronavirus drug development program is unaffected by the recent discovery of a new strain of Coronavirus in Southern England.

• Sunshine Biopharma Pays Off Convertible Notes in Cash Preventing New Shares From Hitting the Market

  12/3/2020

  Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has paid off just over $100,000 worth of convertible notes associated with the Company.

• Sunshine Biopharma Receives Third Tranche From Previously Announced $2,000,000 + Financing for Coronavirus Treatment

  12/1/2020

  Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received the third tranche of funding under the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc.